公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2021 | Genomic Profiling of Premenopausal HR+ and HER2– Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib | Bardia A.; Su F.; Solovieff N.; Im S.-A.; Sohn J.; Lee K.S.; Campos-Gomez S.; Jung K.H.; Colleoni M.; V?zquez R.V.; Franke F.; Hurvitz S.; Harbeck N.; Chow L.; Taran T.; Lorenc K.R.; Babbar N.; Tripathy D.; YEN-SHEN LU | JCO Precision Oncology | |||
2020 | Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7) | Harbeck N.; Franke F.; Villanueva-Vazquez R.; YEN-SHEN LU ; Tripathy D.; Chow L.; Babu G.K.; Im Y.-H.; Chandiwana D.; Gaur A.; Lanoue B.; Rodriguez-Lorenc K.; Bardia A. | Therapeutic Advances in Medical Oncology | 36 | 31 | |
2022 | Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR+/HER2- Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial | YEN-SHEN LU ; Im S.-A.; Colleoni M.; Franke F.; Bardia A.; Cardoso F.; Harbeck N.; Hurvitz S.; Chow L.; Sohn J.; Lee K.S.; Campos-Gomez S.; Vazquez R.V.; Jung K.H.; Babu K.G.; Wheatley-Price P.; De Laurentiis M.; Im Y.-H.; Kuemmel S.; El-Saghir N.; O'Regan R.; Gasch C.; Solovieff N.; Wang C.; Wang Y.; Chakravartty A.; Ji Y.; Tripathy D. | Clinical Cancer Research | 88 | 38 |